AstraZeneca among 10 drugmakers to partner with Genomics England

27 March 2015

Ten drugmakers have partnered with Genomics England to take advantage of developments that have come from the 100,000 Genomes Project.

Companies including AstraZeneca (LSE: AZN), GlaxoSmithKline (LSE: GSK) and AbbVie (NYSE: ABBV) have formed the Genomics Expert Network for Enterprises (GENE) Consortium to oversee a year-long trial involving a selection of whole-genome sequences in oncology and rare diseases.

Genomics England says the project "will transform treatment for patients with cancer and rare diseases, providing faster access to the right treatment and personalized care to tackle complex diseases.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK